市場調查報告書
商品編碼
1256375
聯網藥物輸送設備市場 - 按設備按技術按應用按最終用途預測 2023-2032 年Connected Drug Delivery Devices Market - By Device, By Technology, By Application, By End-use & Forecast, 2023 - 2032 |
由於機器學習和人工智能 (AI) 等技術在醫療保健和藥物輸送領域的應用越來越廣泛,預計聯網藥物輸送設備市場到 2032 年將取得顯著增長。
此外,實時數據在醫療保健領域日益重要也將推動市場擴張。 此外,市場參與者採取的一些將先進技術融入其設備的舉措將推動業務增長。
例如,Becton Dickinson (BD) 已與 Biocorp 簽署協議,在註射器中使用近場通信標籤。 該協議將把 Biocorp 的 Injay 設備整合到 UltraSafePlus 預裝注射器中,提供增強的數字連接,可用於存儲注射日期、批號和有效期等信息。
總體而言,互聯給藥設備行業按設備、技術、應用、最終用途和區域進行細分。
在設備方面,集成設備領域將在 2023 年至 2032 年期間呈現大幅增長。 慢性病患病率的上升、健康和疾病意識的提高、電信行業的崛起以及政府舉措的增加預計將在未來幾年推動市場擴張。
在技術方面,Wi-Fi 技術領域預計到 2032 年的複合年增長率將達到 28.5%。 不斷創新導致醫療設備採用最新技術的情況有所增加。 此外,消費者對用於跟蹤每日藥物攝入量的幾種連接藥物輸送設備技術的認識不斷提高,將進一步推動對內置 WiFi 的連接藥物輸送設備的需求。
按應用劃分,到 2022 年,過敏反應部分的收入將超過 3100 萬美元。 由於在過敏反應患者中越來越多地使用連接的藥物輸送設備進行快速給藥,預計該細分市場將出現顯著增長。 過敏反應病例的增加將進一步促進整個市場的增長。 歐洲數據顯示,每年每 10 萬人因各種原因引起的過敏反應發生率為 1.5 至 7.9 例。
從最終用途的角度來看,家庭護理領域將在 2022 年佔據重要的市場份額。 該設備的不斷發展使其使用變得簡單方便。 此外,家庭護理中對自我管理療法的日益偏好將推動該行業的發展。
按地區劃分,亞太地區的互聯給藥設備市場預計在整個預測期內都將增長。 製藥行業的持續增長將推動市場的增長,因為它為新產品和先進產品提供了有利可圖的機會。 此外,越來越多地採用新技術和政府加大力度支持製藥業的發展也將支持市場的發展。
Connected Drug Delivery Devices Market is anticipated to garner substantial gains through 2032 owing to the increasing adoption of technologies such as machine learning and artificial intelligence (AI) in healthcare and drug delivery. Besides, the rising importance of real-time data across the healthcare sector will propel the market expansion. In addition, numerous initiatives taken up by market players to incorporate advanced technology in devices will promote the business growth.
Beckton Dickinson (BD), for instance, inked a deal with Biocorp to leverage its near-field communication tags in injectable devices. The deal would see Biocorp's Injay device incorporated in UltraSafePlus prefilled syringes, offering them increased digital connectivity that can be used to accumulate information such as injection time and date, batch number, and expiration date.
Overall, the connected drug delivery devices industry is segmented in terms of device, technology, application, end-use and region.
Based on devices, the integrated devices segment will showcase considerable growth during 2023-2032. The increasing prevalence of chronic diseases, rising awareness regarding health and illness, rising telecommunication industry, and surging government initiatives will propel the market expansion during the ensuing years.
Considering the technology, the Wi-Fi technology segment is anticipated to depict over 28.5% CAGR through 2032. Constant innovations have resulted in the increasing adoption of the latest technologies in medical devices. Besides, the rising consumer awareness regarding several connected drug delivery device technologies to track their daily medication will further drive the demand for WiFi embed connected drug delivery devices.
By application, the anaphylaxis segment accounted for more than USD 31 million in 2022. The segment will see huge growth owing to the increasing use of connected drug delivery devices in anaphylaxis patients for quick drug administration. Increasing cases of anaphylaxis would further benefit the overall market growth. European data depicted that the incidence rates for all-causes of anaphylaxis vary between 1.5 to 7.9 per 100,000 person per year.
In terms of end-use, the homecare settings segment held a considerable market share in 2022. Constant device development have made their use easy and convenient. Furthermore, an increasing preference for self-administered therapy at homecare will drive the industry growth.
Geographically, the Asia Pacific connected drug delivery devices market will grow throughout the forecast period. The constantly increasing pharmaceutical industry will assist the market progression as it offers lucrative opportunities for new and advanced products. Besides, the increasing adoption of new technologies and rising government initiatives for supporting the growth of the pharma industry will boost market development.